InflammationNCT07190924
Inflammatory Responses After CrossFit and Resistance Trainings in Untrained Subjects
A study testing 12 week training in people with Inflammation and Oxidative Stress, run by Habil Hamdouni at 1 site in Tunisia.
Trial summary
Considering the remarkable increase of the fitness programs, the purpose of this study was to assess and compare the effect of Crossfit (CF) and periodized resistance (RT) trainings on inflammatory/oxidative responses in untrained individuals. Read more about this study
- Who is it for?
- Any ageHealthy volunteers can take part
- Conditions the study is for
- Inflammation, Oxidative Stress, Plasma Volume
- What is being tested?
- 12 week training
- Type of treatment
- Lifestyle or therapy programme
- Could I receive a placebo?
- No, everyone receives an active treatment
- How many people
- 24 participants
- Where
- 1 siteTunisia
- Study dates
- 8 Nov 2021to 17 Apr 2022
- Phase
- Interventional
- Are there results?
- None posted in the registry
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages Any age
- All sexes
- Healthy volunteers accepted
- Child, Adult, Older adult
Who may be able to join
- Participants must be non-smokers,
- Participants should not suffer from respiratory issues
- Participants should have healthy kidney and liver
- Participants have no metabolic and neurological disorders
Who cannot join
- The use of medications during the previous 4 weeks
- Consumption of any product related to anti-inflammatory/oxidative supplements
Trial locations and contacts
1 site in 1 country.
Tunisia1 site
Institut Supérieur du Sport et de l'Education Physique de Ksar-Saïd
Aryanah, Ariana Governorate, 2073
About this study
Official title: The Effect of a CrossFit Training Program on Physical, Physiological, and Hormonal Responses in Untrained Subjects
Considering the remarkable increase of the fitness programs, the purpose of this study was to assess and compare the effect of Crossfit (CF) and periodized resistance (RT) trainings on inflammatory/oxidative responses in untrained individuals.
Twenty-four participants (20 men and 4 women, age= 25.7 ± 2.2 years, BMI= 25.7 kg.m-2) were randomly assigned into 12 weeks of these trainings with a rate of five sessions/week. Before and after intervention, participants anthropometric data and graded exercise tests were performed. Before (pre), immediately after (post) and 60min after test (p60) a 20mL venous blood sample were drawn for a later measure of c-reactive protein (CRP), interleukin 1 beta (IL-1ß), tumor necrosis factor alpha (TNF-α), interleukin 6 (IL-6), interleukin 10 (IL-10), thiobarbituric acid reactive substances (TBARS), antioxidant enzymes catalase (CAT) and glutathione peroxidase (GPx).
- Conditions
- Inflammation, Oxidative Stress, Plasma Volume, Hormones
- Being tested
- 12 week training
- Medical subject headings
- Inflammation
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
12 week trainingBehavioural
Anti-inflammatory and oxidative environment following 12-weeks of CF training by evaluating inflammatory markers and oxidative precursors in untrained participants
12 week trainingBehavioural
Anti-inflammatory and oxidative environment following 12-weeks of resistance training by evaluating inflammatory markers and oxidative precursors in untrained participants
| Study group | Role | What they receive |
|---|---|---|
| CrossFit | Experimental | High intensity functional training Receives: Behavioral: 12 week training |
| Resistance | Experimental | Periodized resistance training Receives: Behavioral: 12 week training |
What is being measured
The primary outcome is the main question the study is designed to answer.
Inflammatory marker
c-reactive protein (CRP),
Measured: Participants data were performed in one day before beginning the 12 week intervention and one day after the last session
Inflammatory marker
interleukin 1 beta (IL-1ß)
Measured: Participants data were performed in one day before beginning the 12 week intervention and one day after the last session
Inflammatory marker
tumor necrosis factor alpha (TNF-α)
Measured: Participants data were performed in one day before beginning the 12 week intervention and one day after the last session
Inflammatory marker
interleukin 6 (IL-6)
Measured: Participants data were performed in one day before beginning the 12 week intervention and one day after the last session
Inflammatory marker
interleukin 10 (IL-10)
Measured: Participants data were performed in one day before beginning the 12 week intervention and one day after the last session
Oxidative stress
thiobarbituric acid reactive substances (TBARS)
Measured: Participants data were performed in one day before beginning the 12 week intervention and one day after the last session
Oxidative stress
antioxidant enzymes catalase (CAT)
Measured: Participants data were performed in one day before beginning the 12 week intervention and one day after the last session
Oxidative stress
glutathione peroxidase (GPx)
Measured: Participants data were performed in one day before beginning the 12 week intervention and one day after the last session
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted24 Sep 2025
- Study start8 Nov 2021
- Primary completion8 Feb 2022
- Study completion17 Apr 2022
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for InflammationStudies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase N/A
- Primary purpose
- Treatment
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- None (open label)
- Enrolment
- 24 participants (actual)
Sponsor and investigators
- Lead sponsor
- Habil Hamdouni
- Sponsor type
- University, hospital or other
- Responsible party
- Sponsor-investigator, Habil Hamdouni, Institut Supérieur du Sport et de l'Education Physique de Ksar-Saïd
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT07190924
- Sponsor's protocol ID
- ISS-1386
- Status last verified
- Sep 2025
- First submitted
- 14 Sep 2025
- Last updated
- 24 Sep 2025
- Results posted
- No
- Data monitoring committee
- Yes
- FDA-regulated drug
- No
- FDA-regulated device
- No
- Individual data sharing
- Undecided: Under negotation
Study at a glance
From the registry record, last updated by the sponsor on 24 Sep 2025. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- The Effect of a CrossFit Training Program on Physical, Physiological, and Hormonal Responses in Untrained Subjects
- ClinicalTrials.gov ID
- NCT07190924
- Acronym / sponsor ID
- ISS-1386
- Conditions
- Inflammation, Oxidative Stress, Plasma Volume, Hormones
- Study type
- Interventional
- Recruitment status
- Completed
- Enrolment
- 24 participants (actual)
- Lead sponsor
- Habil HamdouniUniversity, hospital or other
- Study start
- 8 Nov 2021 (actual)
- Primary completion
- 8 Feb 2022 (actual)
- Study completion
- 17 Apr 2022 (actual)
- First posted
- 24 Sep 2025 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
Considering the remarkable increase of the fitness programs, the purpose of this study was to assess and compare the effect of Crossfit (CF) and periodized resistance (RT) trainings on inflammatory/oxidative responses in untrained individuals.
Twenty-four participants (20 men and 4 women, age= 25.7 ± 2.2 years, BMI= 25.7 kg.m-2) were randomly assigned into 12 weeks of these trainings with a rate of five sessions/week. Before and after intervention, participants anthropometric data and graded exercise tests were performed. Before (pre), immediately after (post) and 60min after test (p60) a 20mL venous blood sample were drawn for a later measure of c-reactive protein (CRP), interleukin 1 beta (IL-1ß), tumor necrosis factor alpha (TNF-α), interleukin 6 (IL-6), interleukin 10 (IL-10), thiobarbituric acid reactive substances (TBARS), antioxidant enzymes catalase (CAT) and glutathione peroxidase (GPx).
Study design
- Primary purpose
- Treatment
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- None (open label)
- Number of arms
- 2
| Arm | Type | Receives |
|---|---|---|
| CrossFit | Experimental | Behavioral: 12 week trainingHigh intensity functional training |
| Resistance | Experimental | Behavioral: 12 week trainingPeriodized resistance training |
Who may qualify
- Sex
- All
- Healthy volunteers
- Accepted
- Age groups
- Child, Adult, Older adult
Key inclusion criteria (4 listed)
- Participants must be non-smokers,
- Participants should not suffer from respiratory issues
- Participants should have healthy kidney and liver
- Participants have no metabolic and neurological disorders
Key exclusion criteria (2 listed)
- The use of medications during the previous 4 weeks
- Consumption of any product related to anti-inflammatory/oxidative supplements
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| 12 week trainingAnti-inflammatory and oxidative environment following 12-weeks of CF training by evaluating inflammatory markers and oxidative precursors in untrained participants | Behavioural | CrossFit |
| 12 week trainingAnti-inflammatory and oxidative environment following 12-weeks of resistance training by evaluating inflammatory markers and oxidative precursors in untrained participants | Behavioural | Resistance |
Primary outcome
Inflammatory marker
Time frame: Participants data were performed in one day before beginning the 12 week intervention and one day after the last session
c-reactive protein (CRP),
Inflammatory marker
Time frame: Participants data were performed in one day before beginning the 12 week intervention and one day after the last session
interleukin 1 beta (IL-1ß)
Inflammatory marker
Time frame: Participants data were performed in one day before beginning the 12 week intervention and one day after the last session
tumor necrosis factor alpha (TNF-α)
Inflammatory marker
Time frame: Participants data were performed in one day before beginning the 12 week intervention and one day after the last session
interleukin 6 (IL-6)
Inflammatory marker
Time frame: Participants data were performed in one day before beginning the 12 week intervention and one day after the last session
interleukin 10 (IL-10)
Oxidative stress
Time frame: Participants data were performed in one day before beginning the 12 week intervention and one day after the last session
thiobarbituric acid reactive substances (TBARS)
Oxidative stress
Time frame: Participants data were performed in one day before beginning the 12 week intervention and one day after the last session
antioxidant enzymes catalase (CAT)
Oxidative stress
Time frame: Participants data were performed in one day before beginning the 12 week intervention and one day after the last session
glutathione peroxidase (GPx)
Results and safety
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 24 Sep 2025.
- Individual participant dataSharing planned: Undecided. Under negotation
Related trials for Inflammation
Not yet recruitingPhase 2/3
A Pivotal Safety and Immunogenicity GBS-NN/NN2 Vaccine Maternal Immunisation Trial
Streptococcus Agalactiae Infection, Neonatal Sepsis
RecruitingPhase 1
Pilot Study to Identify the Mediators and Inflammatory Cell Surface Receptors Involved in Allergic Airway Inflammation
Asthma
RecruitingPhase 4
Lidocaine Infiltration and Neuroimmunomodulation in Head and Neck Cancer Surgery
Head and Neck Cancer (H&N)
Active, not recruiting
CT for Personalized Mechanical Ventilation
Ventilator-Induced Lung Injury, Sepsis Syndrome
RecruitingPhase 4
A Study to Compare the Efficacy and Safety of Extended and Intermittent Infusion of Beta-lactams in Critically Ill Paediatric Patients
Infection, Sepsis
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
The record lists no contact. Use the official record to reach the sponsor.
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
A study testing 12 week training in people with Inflammation and Oxidative Stress, run by Habil Hamdouni at 1 site in Tunisia.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 4 inclusion and 2 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: finished, as of the sponsor's last update on 24 Sep 2025. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in Tunisia. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Inflammatory marker (time frame: Participants data were performed in one day before beginning the 12 week intervention and one day after the last session). The study lists 8 primary outcomes in all. It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 24 Sep 2025.